Physician profile
Patrick Snyder
NPI 1194160770
$1,531.37
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2021: $135 · 2022: $125 · 2023: $325 · 2024: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $566 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.26 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $420.46 | 2019 | |
| Janssen Biotech, INC. | $353.09 | 2023-2024 | Stelara, Tremfya |
| Medtronic, INC. | $290.62 | 2022-2023 | Endoflip, Gi Genius, Manoscan |
| Olympus America INC. | $171.90 | 2021-2024 | Visiglide, Gastrointestinal Videoscope, Evis Exera III Colonovideoscope |
| Enterra Medical, INC. | $109.16 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.41 | 2019 | |
| Merck Sharp & Dohme LLC | $43.60 | 2019 | |
| Alexion Pharmaceuticals, INC. | $40.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.87 | 2019 | |
| Aries Pharmaceuticals, INC. | $18.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.